Article
Biochemistry & Molecular Biology
Natan J. W. Straathof, Charlotte B. Magnus, Fedor Zhuravlev, Andreas I. Jensen
Summary: This study presents a method for synthesizing [16]andS(4) and strategies for preparing bifunctional derivatives, which can facilitate the labeling of a variety of molecules with relevant soft radiometal ions, contributing to the development of radiopharmaceutical chemistry.
Review
Urology & Nephrology
Mohammad S. Sadaghiani, Sara Sheikhbahaei, Rudolf A. Werner, Kenneth J. Pienta, Martin G. Pomper, Lilja B. Solnes, Michael A. Gorin, Nae-Yuh Wang, Steven P. Rowe
Summary: PRLT treatment shows promising potential in treating CRPC, with a relatively high number of PSA responders and a low rate of severe toxicity.
Article
Chemistry, Multidisciplinary
Jiwei Zheng, Wanyi He, Jing Li, Xuejia Feng, Yanyan Li, Binghua Cheng, Yimin Zhou, Meiqing Li, Ke Liu, Ximing Shao, Jianchao Zhang, Hongchang Li, Liang Chen, Lijing Fang
Summary: The novel IFLD strategy utilizes integrin and lysosome to establish a targeted protein degradation approach that effectively degrades extracellular and cell membrane proteins. Its feasibility has been demonstrated in vitro and in vivo, expanding the toolbox for protein regulation.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2022)
Review
Endocrinology & Metabolism
Mohammad S. Sadaghiani, Sara Sheikhbahaei, Rudolf A. Werner, Kenneth J. Pienta, Martin G. Pomper, Michael A. Gorin, Lilja B. Solnes, Steven P. Rowe
Summary: PSMA-targeted endoradiotherapy/radioligand therapy (PRLT) is effective in castration resistant prostate cancer (CRPC). The evaluation of PRLT mainly focuses on prostate-specific antigen (PSA) decline and overall survival (OS). The study found that PRLT can lead to a higher proportion of patients with PSA decline and prolong overall survival in CRPC patients.
Review
Oncology
Soghra Farzipour, Zahra Shaghaghi, Sahar Abbasi, Hajar Albooyeh, Maryam Alvandi
Summary: Targeted Alpha Therapy (TAT) is a rapidly growing option for cancer therapy, delivering high radiation dose selectively to cancer cells through alpha-emitting radionuclides conjugated to tumor-targeting vectors. Numerous clinical trials and preclinical researches have investigated the efficacy of Ac-225, Bi-212, At-211, Bi-213, and Ra-223 in treating smaller tumor burdens, micro-metastatic disease, and post-surgery residual disease. This review highlights recent advancements in TAT-based targeting vectors and chelating agents, providing insights for future researches.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2022)
Article
Oncology
Antje Dietrich, Michael Andreeff, Lydia Koi, Ralf Bergmann, Maik Schubert, Lena Schreiner, Steffen Loeck, Wiebke Sihver, Robert Freudenberg, Sandra Hering, Hans-Juergen Pietzsch, Joerg Steinbach, Joerg Kotzerke, Michael Baumann, Mechthild Krause
Summary: Combining Y-90-labeled anti-EGFR antibody with fractionated radiotherapy showed promise in enhancing tumor control in head and neck squamous cell carcinoma xenograft tumors. Low to moderate external beam doses were found to enhance antibody uptake, leading to substantially increased tumor control compared to radiotherapy alone. The results suggest that this combination therapy has the potential to improve curative treatment outcomes.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Engineering, Biomedical
Mohammad Taleb, Mona Atabakhshi-Kashi, Yazhou Wang, Hamideh Rezavani Alanagh, Zeinab Farhadi Sabet, Fenfen Li, Keman Cheng, Chen Li, Yingqiu Qi, Guangjun Nie, Zhao Ying
Summary: The study demonstrates the use of peptide nanoparticles to modulate both tumor vasculature and immune systems for synergistic tumor suppression. Increasing intratumoral infiltration of immune cells through vascular normalization, while simultaneously inhibiting the PD-L1 immune checkpoint function, reactivates effective immune responses against tumors.
ADVANCED HEALTHCARE MATERIALS
(2021)
Review
Radiology, Nuclear Medicine & Medical Imaging
Shishu Kant Suman, Suresh Subramanian, Archana Mukherjee
Summary: Targeted molecular radionuclide therapy (MRT) shows potential for treating cancers of multiple origins. Combination radionuclide therapy (CRT) utilizes a combination of radiolabeled targeting agents with chemotherapy and beam radiation therapy for enhanced therapeutic index. Success lies in understanding radiobiological principles and activated pathways.
NUCLEAR MEDICINE AND BIOLOGY
(2021)
Review
Oncology
Lauren Lukas, Hualin Zhang, Karen Cheng, Alan Epstein
Summary: This review provides an overview of the nontargeted immune effects of spatially fractionated radiation therapy (SFRT) and explores strategies to enhance its immunomodulatory potential in combination with immunotherapy (IT).
CURRENT ONCOLOGY REPORTS
(2023)
Article
Pharmacology & Pharmacy
Mitsuyoshi Yoshimoto, Yukie Yoshii, Hiroki Matsumoto, Mitsuhiro Shinada, Masashi Takahashi, Chika Igarashi, Fukiko Hihara, Tomoko Tachibana, Ayano Doi, Tatsuya Higashi, Hirofumi Fujii, Kohshin Washiyama
Summary: This study evaluated the feasibility of various chelators for reducing and excreting free Ac-225, finding that aminopolycarboxylate chelators with five and six carboxylic groups, Ca-DTPA and Ca-TTHA, were effective for whole-body clearance of free Ac-225.
Article
Medicine, Research & Experimental
Thom G. A. Reuvers, Nicole S. Verkaik, Debra Stuurman, Corrina de Ridder, Marian C. Clahsen-van Groningen, Erik de Blois, Julie Nonnekens
Summary: Peptide receptor radionuclide therapy (PRRT) can improve the progression-free survival and quality of life of neuroendocrine tumor (NET) patients, but complete cures are rare and dose-limiting toxicity has been reported. PRRT induces DNA damage, with DNA double strand breaks (DSBs) being the most cytotoxic. DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is involved in DSB repair and inhibiting it can potentially enhance PRRT efficacy without increasing the dosage.
Article
Biochemistry & Molecular Biology
Jan Hajduch, Benjamin Fabre, Benjamin Klopp, Radek Pohl, Milos Budesinsky, Veronika Solinova, Vaclav Kasicka, Cemal Kopruluoglu, Saltuk Mustafa Eyrilmez, Martin Lepsik, Pavel Hobza, Katarina Mitrova, Marta Lubos, Maria Soledad Garre Hernandez, Jiri Jiracek
Summary: The study prepared four multi-orthogonal molecular scaffolds for synthesizing compounds mimicking the insulin receptor, with adamantane-derived compounds binding more effectively. Molecular dynamics simulations suggested that spacers provide greater flexibility for increased binding affinity.
BIOORGANIC CHEMISTRY
(2021)
Article
Engineering, Biomedical
Teresa L. Palmer, Kinga Tkacz-Stachowska, Roar Skartlien, Nasrin Omar, Sindre Hassfjell, Andreas Mjos, Johannes Bergvoll, Ellen M. Brevik, Olaug Hjelstuen
Summary: A microdosimetry model was developed to predict cell viability when exposed to low energy, short-range auger electrons. The model was tested with LNCaP prostate cancer cells irradiated with Lu-177 and Tb-161, showing that Tb-161 was more efficient due to its short-range auger electrons. The results suggest that imaging-based microdosimetry could be useful for evaluating the therapeutic effects of different radionuclide candidates.
PHYSICS IN MEDICINE AND BIOLOGY
(2021)
Article
Oncology
Liqun Wang, Ren Luo, Kateryna Onyshchenko, Xi Rao, Meidan Wang, Beatrice Menz, Simone Gaedicke, Anca-Ligia Grosu, Elke Firat, Gabriele Niedermann
Summary: This study investigates the use of low-dose Doxil in combination with RT and alpha PD-1 to enhance the abscopal effect on non-irradiated tumors. The results demonstrate that the combination therapy significantly increases the antitumor response, particularly in non-irradiated tumors. Moreover, the study suggests that the mtDNA/cGAS/STING/IFN-I pathway plays an important role in the immunogenic and immunomodulatory effects of Doxil.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Giulia Tamborino, Julie Nonnekens, Marijke De Saint-Hubert, Lara Struelens, Danny Feijtel, Marion de Jong, Mark W. Konijnenberg
Summary: The study aimed to build a refined dosimetry model for Lu-177-DOTATATE in vivo experiments to establish the correlation between absorbed dose and double-strand break induction and cell death. By imaging and analyzing different parameters, such as absorbed dose and in vivo survival, the radiosensitivity parameters and relative biological effectiveness were determined, which can contribute to the optimization of treatment protocols.
JOURNAL OF NUCLEAR MEDICINE
(2022)
